Search Bar & Filters
Found 1002 Actively Recruiting clinical trials
Actively Recruiting
This research aims to study how a produce prescription program called Eat Well affects the health and healthcare use of Veterans, especially those facing food insecurity in North Carolina. Food insecurity, meaning limited access to safe and healthy food, affects about one in four Veteran households and can worsen conditions like diabetes and increase healthcare costs. The study focuses on Veterans with hypertension and related conditions to learn how providing healthy food support may improve their outcomes. Participants will be randomly assigned to one of three groups receiving 100 per month in Eat Well benefits for 6 months, receiving 100 per month in Eat Well benefits for 12 months, or continuing with the standard care without the Eat Well program. Those in the Eat Well groups will also receive guidance on enrolling in VA programs for health and nutrition support. The study will compare these groups over a 12-month period to assess differences in health and healthcare usage. Throughout the study, researchers will monitor changes in participants systolic blood pressure as the primary outcome, as well as hemoglobin A1c levels and healthcare visits such as inpatient, outpatient, emergency department, and health promotion program participation. The study will enroll 1,500 Veterans and collect data over the course of 12 months to evaluate the impact of the produce prescription program on health and resource use.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating the use of 129Xe MRIMRS biomarker signatures to non-invasively monitor changes in the lungs of patients with pulmonary arterial hypertension PAH who are treated with sotatercept. The study aims to predict short- and long-term responses to sotatercept and improve assessment of treatment outcomes compared to current standard methods. PAH involves blood vessel remodeling in the lungs that leads to heart failure and reduced lung function, and sotatercept is being studied for its potential to reverse these changes. Participants with PAH receiving sotatercept as part of their clinical care will undergo 129Xe MRIMRS scans at baseline, 3 months, and 12 months. These scans measure ventilation defects, blood volume in lung capillaries, lung wall thickness and inflammation, and heart-related oscillations. Alongside the imaging, standard assessments such as laboratory tests, heart ultrasound, NTproBNP blood tests, and a 6-minute walk test will be performed at each visit. During the study, participants will have multiple visits to complete imaging, lab work, and functional tests to monitor lung and heart function. Researchers will track changes in specific MRIMRS biomarkers and cardiogenic oscillation amplitudes over time to evaluate treatment effects. The study includes safety monitoring and will last until at least 12 months after starting sotatercept treatment.
Actively Recruiting
Researchers are studying pulmonary arterial hypertension PAH, including its common subtypes idiopathic PAH IPAH and connective tissue disease-associated PAH PAH-CTD. The study aims to develop pulmonary vascular biomarker signatures using hyperpolarized 129Xe MRI to differentiate these subtypes and to evaluate the ability of this imaging to monitor disease progression and treatment response over time. Additional assessments such as laboratory tests, echocardiography, and six-minute walk distance 6MWD are also used to support these evaluations. The study is observational and enrolls 20 subjects divided into two groups 10 with IPAH and 10 with PAH-CTD. Participants will undergo hyperpolarized 129Xe MRI and MR spectroscopy at baseline, 3 months, 6 months, and 12 months. Alongside imaging, data from standard clinical assessments including labs, echocardiography, and 6MWD will be collected at these same timepoints to track changes. Participants will be monitored for changes in pulmonary vascular remodeling, red blood cell oscillation amplitude, 6MWD, NTproBNP levels, and WHO functional class over one year. Safety is assessed by tracking adverse events, serious adverse events, withdrawals, and specific examinations such as electrocardiograms and vital signs. The total follow-up period for each participant is one year, with multiple scheduled evaluations to comprehensively assess disease status and response.
Actively Recruiting
Healthy Volunteer
This NIH-sponsored study aims to characterize three biomarkers derived from 129Xe gas exchange MRI and understand how they change in response to interventions. The study focuses on markers derived from the interaction of 129Xe with pulmonary capillary red blood cells RBCs, specifically RBC transfer MRI, cardiogenic oscillations in 129Xe-RBC signal amplitude, and the 129Xe-RBC chemical shift. The study population includes healthy volunteers, patients scheduled to undergo transfusion or phlebotomy, patients with dyspnea, interstitial lung disease ILD, idiopathic pulmonary fibrosis IPF, non-specific interstitial pneumonias NSIP, chronic hypersensitivity pneumonitis cHP, sarcoid, chronic thromboembolic pulmonary hypertension CTEPH, and acute pulmonary embolism.
Actively Recruiting
Researchers are evaluating the use of a new imaging technology called 4D Microscope Integrated Optical Coherence Tomography 4D MIOCT integrated into a Zeiss Artevo 800 surgical microscope. This observational study aims to capture detailed images during eye surgeries for various ocular diseases, including corneal and retinal conditions. The goal is to assess the systems ease of use, safety, and ability to visualize normal and abnormal microanatomy during surgery. Participants will undergo their planned eye surgeries while the investigational 4D MIOCT device captures images of one or both eyes during the procedures. No additional treatments or interventions are performed for research purposes. The study will analyze the collected images offline and compare them with existing clinical imaging from the participants medical records to determine if new information is gained. During the study, researchers will review participants medical records from up to three prior eye care visits to collect clinical data related to eye health and treatments. The primary outcome is to measure the ease of use of the 4D MIOCT system during surgery. Secondary outcomes include evaluating the surgical workflow and detecting normal and abnormal microanatomy through the images. Participation involves imaging during surgery and no added risks beyond the standard surgical care, with study completion expected by October 2027.
Actively Recruiting
Researchers are evaluating KTX-2001, alone and combined with darolutamide, in men with metastatic castration-resistant prostate cancer mCRPC. This Phase 1, open-label study aims to assess the safety, dosage limits, how the drugs behave in the body, and preliminary effectiveness in treating mCRPC. The trial also seeks to establish recommended doses for future studies. Participants receive escalating doses of KTX-2001 by mouth either alone or together with oral darolutamide at a total daily dose of 1200 mg. The study has two parts Part A focuses on KTX-2001 alone, and Part B studies the combination with darolutamide. Dose escalation continues to determine safe and tolerable levels. During the study, participants undergo baseline and on-treatment biopsies when feasible, imaging scans to confirm metastatic disease, and regular safety monitoring. Researchers measure dose-limiting toxicities within 21 days to find the maximum tolerated dose, along with pharmacokinetics, safety events over up to 3 years, and recommended dosing. Participants are closely observed throughout treatment and follow-up periods until study completion.
Actively Recruiting
Researchers are studying ways to prevent cytomegalovirus CMV infection in children and adolescents who have received a kidney transplant and weigh less than 40 kilograms. This trial focuses on understanding how the drug letermovir behaves in the body over time and assessing its safety and tolerance in this young population. The study is a phase 1, open-label, single-arm trial sponsored by Merck Sharp & Dohme LLC. Participants who are between 4 and 52 weeks post-kidney transplant will receive oral letermovir, either as tablets or pellets, or via gastrostomy or nasogastric tube pellets only for 7 consecutive days. The study uses weight-banded dosing to tailor the treatment to each child or adolescents weight. During the study, participants will be closely monitored with blood sampling to measure letermovir levels over a 24-hour period on Day 7. Researchers will also track any adverse events for up to 21 days and note if any participant stops the treatment due to side effects within 7 days. The total study duration for each participant includes the treatment period and safety monitoring, extending until the primary outcome data is collected.
Actively Recruiting
Researchers are evaluating the safety and effects of ETX101, a gene therapy, in children with SCN1A-positive Dravet syndrome. This study includes infants and children from 6 months to under 18 years, with different age groups in each part. It is a Phase 12 multicenter study with open-label and randomized, double-blind, sham delayed-treatment control designs to assess ETX101s impact. The study has three parts Part 1A tests increasing doses of ETX101 in young children aged 6 to under 36 months Part 1B tests one dose level in children aged 48 months to under 18 years Part 2 compares a single dose of ETX101 to a sham procedure in children aged 6 to under 48 months. Part 2 participants are randomly assigned to treatment or sham groups in a 21 ratio, with masking through 52 weeks. Participants will be involved in treatment and observation over up to 52 weeks post-dosing, with monitoring of monthly seizure frequency and developmental assessments using Bayley-4 and Vineland-3 scales. Researchers will measure changes in seizures and cognitive and adaptive behaviors. Safety and efficacy are tracked through clinical evaluations, and the primary outcome focuses on seizure frequency changes from before treatment to weeks 5 through 52.
1-10 of 1,002
1